Updates are available Erratum dated 2016-07-19
Click to view Erratum: https://doi.org/10.1038/nchembio0816-656
-
Authors
Pacold, Michael E http://orcid.org/0000-0003-3688-2378
Brimacombe, Kyle R
Chan, Sze Ham
Rohde, Jason M
Lewis, Caroline A
Swier, Lotteke J Y M
Possemato, Richard
Chen, Walter W
Sullivan, Lucas B
Fiske, Brian P
Cho, Steve
Freinkman, Elizaveta
Birsoy, Kıvanç
Abu-Remaileh, Monther
Shaul, Yoav D
Liu, Chieh Min
Zhou, Minerva
Koh, Min Jung
Chung, Haeyoon
Davidson, Shawn M
Luengo, Alba
Wang, Amy Q
Xu, Xin
Yasgar, Adam
Liu, Li
Rai, Ganesha
Westover, Kenneth D
Vander Heiden, Matthew G
Shen, Min
Gray, Nathanael S http://orcid.org/0000-0001-5354-7403
Boxer, Matthew B
Sabatini, David M
- License Information
-
More Information
Article History
Received: 16 December 2015
Accepted: 24 March 2016
First Online: 25 April 2016
Change Date: 28 June 2016
Change Type: Corrigendum
Change Details: In the version of this article initially published, the author omitted some funding sources: NIH (R03 DA034602-01A1, R01 CA129105, R01 CA103866, and R37 AI047389 to D.M.S.) and the US Department of Defense (W81XWH-14-PRCRP-IA to D.M.S.). The error has been corrected in the HTML and PDF versions of the article.
Competing interests
: D.M.S. is a founder and holds equity in Raze Therapeutics, which has interest in targeting one-carbon metabolism in cancer. M.E.P. is a consultant to and holds equity in Raze Therapeutics.
